Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
Fenlai TAN
Fenlai TAN
Positions:

Chairman

Company:

Lupeng Pharmaceuticals

Fenlai Tan, M.D., Ph.D., is the Chairmen of BOD of Guangzhou Lupeng Pharmaceuticals Co., Ltd. He holds a Ph.D. degree in medical physiology from University of Arkansas for Medical Sciences, and then completed his post-doctoral fellowship at Cleveland Clinic.


Dr. Fenlai Tan has been actively involved in drug development for decades and is especially experienced in clinical study design and implementation for small molecule anti-cancer targeted drugs. He joined Betta Pharmaceuticals in 2007 where he successfully led the phase I, II, III and IV clinical trials of icotinib (an EGFR tyrosine kinase inhibitor) for the treatment of advanced NSCLC harboring EGFR mutation. In 2011, icotinib (Conmana), as the first home-grown anti-cancer targeted drug, was approved by CFDA and launched in China. A comment titled “Icotinib: kick-starting the Chinese anti-cancer drug industry” was published together with the clinical data of the icotinib phase III study (ICOGEN) on the prestigious medical journal, Lancet Oncology. In addition, Dr. Tan oversees the clinical development (phase I-III clinical studies) of many other innovative drugs at Betta in the field of oncology, diabetes, dermatology, ophthalmology, etc. He and his team have conducted more than 30 clinical studies during the past ten years.